Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution.

"Declaration of interests This work was funded by Coave Therapeutics (formerly, Horama). G.M.L. and N.B. are employees of Coave Therapeutics. A.G. is a former employee of Horama and currently consults for Coave Therapeutics. M.W. and G.L.M. are founders and shareholders of Horama/Coave Therapeutics and received financial support as consultants. M.M. and D.D. are inventors on patent WO2017212019A1 that covers chemically modified AAV vectors. Coave Therapeutics holds a license on this patent for use of such modified vectors in ophthalmology."

"This work was funded by Coave Therapeutics (formerly, Horama). G.M.L. and N.B. are employees of Coave Therapeutics. A.G. is a former employee of Horama and currently consults for Coave Therapeutics. M.W. and G.L.M. are founders and shareholders of Horama/Coave Therapeutics and received financial support as consultants. M.M. and D.D. are inventors on patent WO2017212019A1 that covers chemically modified AAV vectors. Coave Therapeutics holds a license on this patent for use of such modified vectors in ophthalmology. We thank the staff of the Boisbonne Center (ONIRIS, Nantes-Atlantic College of Veterinary Medicine, Nantes) where animal research took place. We thank the staff at the Preclinical Analytics Core of TarGeT, UMR 1089 (PAC, INSERM, and Nantes Université) for the molecular analyses performed in this study. We thank Therese Cronin for her careful proofreading. The work was done in Nantes, France. Declaration of interestsThis work was funded by Coave Therapeutics (formerly, Horama). G.M.L. and N.B. are employees of Coave Therapeutics. A.G. is a former employee of Horama and currently consults for Coave Therapeutics. M.W. and G.L.M. are founders and shareholders of Horama/Coave Therapeutics and received financial support as consultants. M.M. and D.D. are inventors on patent WO2017212019A1 that covers chemically modified AAV vectors. Coave Therapeutics holds a license on this patent for use of such modified vectors in ophthalmology."